Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Mesothelin Vaccines and Model Systems and Control of Tumors

a tumor and mesothelin technology, applied in the field of cancer prognosis, cancer prognosis, anticancer drug development, can solve the problems of inability to generate patient-derived t cell lines and clones that can be employed to identify immune relevant tumor targets, and the response to specific human tumor antigens has not yet been correlated, so as to achieve the effect of prolonging the survival tim

Inactive Publication Date: 2009-04-30
THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
View PDF28 Cites 16 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0019]Another aspect of the invention is a method of testing a substance to determine if it is a potential drug for treating a cancer. The cancer may be, for example, an ovarian cancer, a pancreatic cancer, a mesothelioma, or a squamous cell carcinoma. A test substance is contacted with a mouse model. The mouse model comprises a mouse that has been injected with a recombinant mouse cell line. The injection can be accomplished before or after the test substance is contacted with the mouse. The recombinant mouse cell line comprises peritoneal cells which have been transfected by HPV-16 genes E6 and E7 and an activated oncogene. The cell line is capable of forming ascites and tumors upon intraperitoneal injection into an immunocompetent mouse. One determines whether the test substance causes delay of tumor formation or regression of a tumor in the mouse model, diminution of ascites volume in the mouse model, or longer survival time in the mouse model. Any of these effects indicates that the test substance is a potential drug for treating cancer.

Problems solved by technology

Unfortunately, these antigen identification approaches have not been successful for identifying antigens expressed by many other common cancers.
The major limitation has been the inability to generate patient-derived T cell lines and clones that can be employed to identify immune relevant tumor targets.
Furthermore, T cell responses to specific human tumor antigens have not yet been correlated with clinical responses after immunotherapy.
However, it is unclear which of these differentially expressed genes are immunologically relevant for an anti-tumor response.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Mesothelin Vaccines and Model Systems and Control of Tumors
  • Mesothelin Vaccines and Model Systems and Control of Tumors
  • Mesothelin Vaccines and Model Systems and Control of Tumors

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0106]To identify genes that can serve as potential immune targets for the majority of pancreatic adenocarcinoma patients, we focused only on those genes that were non-mutated, overexpressed by the majority of pancreatic cancer patients, and overexpressed by the vaccine cell lines. One gene at the top of this list was mesothelin (20, 21). For comparison and validation purposes we also looked at prostate stem cell antigen (PSCA). SAGE data demonstrated PSCA to be expressed by pancreatic tumors at similar levels to that of mesothelin (22).

[0107]We used the combination of two public use computer algorithms (23-25) to predict peptide nonamers that bind to three common human leukocyte antigen (HLA)-class I molecules. All 14 patients treated with the allogeneic GM-CSF vaccine express at least one of these HLA-Class 1 molecules (Table 2). The predictive algorithm “BIMAS”, ranks potential HLA binding epitopes according to the predictive half-time disassociation of peptide / HLA complexes (23)...

example 2

[0113]To determine if mesothelin and PSCA are recognized by CD8+ T cells, we screened antigen-pulsed T2 cells with CD8+ T cell enriched PBL from patients that have received an allogeneic GM-CSF secreting pancreatic tumor vaccine. We previously reported the association of in vivo post-vaccination delayed type hypersensitivity (DTH) responses to autologous tumor in three of eight patients receiving the highest two doses of vaccine. These “DTH responders” (each of whom had poor prognostic indicators at the time of primary surgical resection (27) are the only patients who remain clinically free of pancreatic cancer >4 years after diagnosis ((27), Table 2). PBL obtained prior to vaccination and 28 days after the first vaccination were initially analyzed. T2-A3 cells pulsed with the two A3 binding epitopes were incubated overnight with CD8+ T cell enriched lymphocytes isolated from the peripheral blood of patient 10 (non-DTH responder who relapsed 9 months after diagnosis) and 13 (DTH res...

example 3

[0118]The above data clearly demonstrate a correlation of in vivo DTH response to autologous tumor and long term disease-free survival with the post-vaccination induction of mesothelin-specific CD8+ T cell responses. It is possible, however, that this correlation represents generalized immune suppression (in the patients who failed to demonstrate post-vaccination DTH responses to their autologous tumor and who had disease progression), rather than a vaccine specific induction of T cell responses to mesothelin in the DTH responder patients who remain disease-free. To demonstrate that the post-vaccination induction of mesothelin-specific CD8+ T cells is tumor antigen-specific, we evaluated each HLA-A2 positive patient for T cell responses to the HLA-A2-binding influenza matrix peptide, M1 (28). We chose the influenza M1 peptide because most patients on the vaccine study had received an influenza vaccine sometime prior to enrollment. As shown in FIG. 3, all HLA-A2 positive patients dem...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
median survival timeaaaaaaaaaa
median survival timeaaaaaaaaaa
median survival timeaaaaaaaaaa
Login to View More

Abstract

Mesothelin can be used as an immunotherapeutic target. It induces a cytolytic T cell response. Portions of mesothelin which induce such responses are identified. Vaccines can be either polynucleotide- or polypeptide-based. Carriers for raising a cytolytic T cell response include bacteria and viruses. A mouse model for testing vaccines and other anti-tumor therapeutics and prophylactics comprises a strongly mesothelin-expressing, transformed peritoneal cell line.

Description

[0001]This application is a continuation-in-part of U.S. application Ser. No. 10 / 618,088, which claims the benefit of provisional U.S. Applications Ser. No. 60 / 395,556, filed Jul. 12, 2002, 60 / 398,217, filed Jul. 24, 2002, Ser. No. 60 / 414,931, filed Sep. 30, 2002, Ser. No. 60 / 475,783 filed Jun. 5, 2003, and Ser. No. 60 / 918,267 filed Mar. 15, 2007. The contents of each of the aforementioned applications are specifically incorporated herein.[0002]This invention was made using funds from the U.S. government. The terms of grants NCI CA62924, NCI RO1 CA72631, NCI RO1 CA71806, U19 CA72108-02, NCDDG RFA CA-95-020, and NCDGG 1U19 CA113341-01 mandate that the U.S. government retains certain rights in the invention.[0003]A portion of the disclosure of this patent document contains material which is subject to copyright protection. The copyright owner has no objection to the facsimile reproduction by anyone of the patent document or the patent disclosure, as it appears in the Patent and Tradem...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/00
CPCA01K2267/0331A61K39/0011A61K2039/505A61K2039/522A61K2039/523A61K2039/53C12N2740/13043A61K2039/57A61K2039/6031C07K16/30C12N15/8509C12N2710/16522A61K2039/55522A61K39/001168A61P35/00A61P37/04C07K14/4748Y02A50/30A61K2039/5154A61K39/0208A61K2039/52A61K2039/55511C07K7/06C12N15/74
Inventor WU, T.C.HUNG, CHIEN-FUJAFFEE, ELIZABETHHRUBAN, RALPH
Owner THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com